Related Experiment Video
Updated: Jan 30, 2026
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Longitudinal Assessment of TAPSE/PASP Ratio and Its Correlation with Clinical Outcomes in Pulmonary Arterial
Tsung-Han Tsai1, Wan-Jing Ho1, Chun-Li Wang1
1Department of Cardiology, Chang Gung Memorial Hospital Linkou Branch, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Background:
The aim of this study was to assess the prognostic significance of the longitudinal tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) ratio as a surrogate marker of right ventricular (RV) to pulmonary arterial (PA) coupling in patients with pulmonary arterial hypertension (PAH).
Methods:
A retrospective cohort study was conducted on patients with PAH. The TAPSE/PASP ratio at baseline and at 3 to 6 months of follow-up was evaluated along with other echocardiographic and clinical parameters.
Results:
The study included 68 patients with PAH, 75% of whom were female, with a mean age of 46 years and a mean follow-up duration of 64 months. At baseline, non-survivors had higher brain natriuretic peptide levels, shorter 6-minute walk distance (6MWD), and worse hemodynamic profiles compared with survivors. A TAPSE/PASP ratio > 0.22 mm/mmHg at baseline and > 0.23 mm/mmHg at 3 to 6 months of follow-up was associated with improved survival. Compared with baseline, survivors had lower pulmonary vascular resistance, lower PASP, and reduced left ventricular eccentricity indexat follow-up. In addition, better outcomes were observed in patients with World Health Organization functional class (WHO FC) I/II and 6MWD > 390 m compared with those in WHO FC III/IV and 6MWD ≤ 390 m.
Conclusions:
The TAPSE/PASP ratio is a noninvasive marker of RV-PA coupling that can provide dynamic prognostic insights in patients with PAH. It may assist in guiding treatment escalation and individualized therapy. Further studies are needed to verify its role and integration into comprehensive PAH risk assessment frameworks.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...